Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ASCO 2023 - Breast Cancer
AMCP Nexus 2022
ASCO 2022 - Wrap Up
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2015
November 2015, Vol 6, No 10
November 2015, Vol 6, No 10
In the Literature - November 2015
In the Literature
November 2015, Vol 6, No 10
Read Article
80-Gene Assay Identifies Distinct Triple-Positive Breast Cancer Subtypes, Guides Therapy Selection
By
Corbin Davis
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
November 2015, Vol 6, No 10
San Francisco, CA—A new genetic test may allow clinicians to improve their therapy decisions by better categorizing patients into specific subtypes compared with conventional immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) subtyping. According to data presented at the 2015 Breast Cancer Symposium, the BluePrint 80-gene assay reclassifies approximately 23% of tumors, allowing for more effective therapy selection, particularly in patients with triple-positive (HER2-positive/hormone receptor–positive) disease.
Read Article
Men’s Health Supplements Have No Value for Patients with Prostate Cancer
By
Phoebe Starr
Prostate Cancer
,
Solid Tumors
November 2015, Vol 6, No 10
San Antonio, TX—Supplements that are often sold in supermarkets and health food stores to promote “men’s health” or “prostate health” do not provide any clinical benefits to men with prostate cancer, according to the results of a retrospective study presented at the 2015 American Society for Radiation Oncology annual meeting. Men’s health supplements did not significantly prevent distant metastasis, prostate cancer–related death, or treatment-related adverse events in this first-of-its-kind study.
Read Article
Oncology News - November 2015
Oncology News
November 2015, Vol 6, No 10
Read Article
Value-Based Oncology Center of Excellence Model
By
Kelly Blair, MPA
Economics & Value
,
Value in Oncology
,
Value-Based Care
November 2015, Vol 6, No 10
“Centers of Excellence” (COEs) is not a new concept in healthcare. The underlying hypothesis is that providers who specialize in a particular procedure or service will produce superior, predictable outcomes. Payers have developed COE networks to manage cost and quality for complex medical conditions for more than 2 decades, steering volume to high-performing providers in exchange for discounted contractual rates. Under significant pressure to reduce the burden of cancer spending, payers are beginning to make bold network decisions, including narrowing networks, but they need precision tools to ensure that quality of care is uncompromised, and even improved, while reining in unsustainable cost trends.
Read Article
Chemotherapy Safe During Pregnancy in Second and Third Trimesters
By
Phoebe Starr
Chemotherapy
,
Pregnancy & Cancer
,
Personalized Medicine
November 2015, Vol 6, No 10
Vienna, Austria—Results from a new study provide reassurance to women who have cancer while pregnant that they can safely receive treatment during the second or third trimester with chemotherapy or radiation without compromising their unborn child. The study showed that children born to mothers who receive chemotherapy or radiation during pregnancy had no impairment in general health, cognition, or cardiac function compared with children born to healthy mothers, said lead investigator Frédéric Amant, MD, PhD, Department of Gynecologic Oncology, University Hospitals Leuven, Belgium.
Read Article
Consuming 4 Cups of Coffee Improves Outcomes in Patients with Stage III Colon Cancer
By
Mary Mosley
GI Cancers
November 2015, Vol 6, No 10
An apple a day keeps the doctor away. And now it seems that 4 cups of coffee a day may reduce recurrence and death in patients with stage III colon cancer after surgical resection and adjuvant chemotherapy, according to a study led by Brendan J. Guercio, MD, Harvard Medical School, Boston.
Read Article
Aprepitant Improves Emesis Control in Patients with Colorectal Cancer
Colorectal Cancer
,
GI Cancers
November 2015, Vol 6, No 10
Barcelona, Spain—Controlling and minimizing nausea and vomiting enables patients with cancer to continue their chemotherapy. A clinical trial reported at the 2015 European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer shows that the newly approved agent aprepitant (Emend), an oral neurokinin (NK)
1
antagonist, improved antiemetic control in patients with colorectal cancer (CRC) who were receiving oxaliplatin-based chemotherapy, according to Junichi Nishimura, MD, Assistant Professor, Osaka University, Japan.
Read Article
Systemic Therapy plus Radiofrequency: Ablation Survival Benefit in Colorectal Liver Metastases
By
Walter Alexander
GI Cancers
November 2015, Vol 6, No 10
Barcelona, Spain—The first randomized study prospectively investigating the efficacy of radiofrequency ablation (RFA) added to standard systemic treatment in patients with unresectable colorectal cancer (CRC) liver metastases revealed progression-free survival (PFS) and overall survival (OS) benefits, according to Theo J.M. Ruers, MD, PhD, Department of Surgery, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Ziekenhuis, Amsterdam.
Read Article
Ramucirumab Confers Survival Benefit in Some Patients with Hepatocellular Carcinoma
By
Walter Alexander
GI Cancers
November 2015, Vol 6, No 10
Barcelona, Spain—In the REACH trial evaluating ramucirumab (Cyramza) as second-line treatment in patients with advanced hepatocellular carcinoma after first-line therapy with sorafenib (Nexavar), overall survival (OS) was improved in the subgroup population with baseline α-fetoprotein of ?400 ng/mL (Child-Pugh class A). The OS benefits in the overall population (Child-Pugh classes A and B) did not reach significance, said lead investigator Andrew X. Zhu, MD, PhD, Massachusetts General Hospital Cancer Center, Boston.
Read Article
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
2.
Navigating Care Programs in the Post-OCM era
3.
Why AVBCC?
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ASCO 2023 - Breast Cancer
AMCP Nexus 2022
ASCO 2022 - Wrap Up
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
VBCC
Print Edition
VBCC
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
VBCC
's
Privacy Policy
, and
VBCC
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION